{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:31:39Z","timestamp":1793334699614,"version":"4.5.0"},"reference-count":43,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p> The advent of antisense oligonucleotide (ASO) therapies in neurodegenerative disorders is associated with enormous hope. Nusinersen treatment was a breakthrough intervention in the recessive disease spinal muscular atrophy, and superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) seems to be the paradigm disease in dominant degenerative diseases. The results of treatment with the ASO tofersen in SOD1-ALS show that the drug has a convincing beneficial effect on ALS caused by SOD1 mutations, that preclinical studies in rodents predicted the therapeutic effect in the human disease, and that clinical efficacy is associated with a specific sequence of effects of the drug on mechanistic and degenerative biomarkers and, subsequently, functional outcomes such as weight stabilization and ALSFRS-R. Therefore, the enthusiasm seems to be justified; but this should be followed by an attempt to obtain further insights with the goal to improve this therapy. In particular, the following issues are only partially resolved: Which mechanisms are responsible for the clinical effect following the downregulation of SOD1 protein by ASOs? Is long-term downregulation of SOD1 function associated with side effects? Is there an autoimmune response caused by this and other ASO? Is prevention of SOD1-associated ALS possible? <\/jats:p>","DOI":"10.1177\/17562864251313915","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T11:00:31Z","timestamp":1737543631000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":20,"title":["Tofersen and other antisense oligonucleotides in ALS"],"prefix":"10.1177","volume":"18","author":[{"given":"Albert","family":"Ludolph","sequence":"first","affiliation":[{"name":"Department of Neurology, Ulm University, Oberer Eselsberg 45, Ulm 89081, Germany"},{"name":"Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Wiesenfarth","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"bibr1-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2010.224501"},{"key":"bibr2-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1159\/000516752"},{"key":"bibr3-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8413-3"},{"key":"bibr4-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-327520"},{"key":"bibr5-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2015.08.005"},{"key":"bibr6-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcad087"},{"key":"bibr7-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcad152"},{"key":"bibr8-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-8735-9"},{"key":"bibr9-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09290-4"},{"key":"bibr10-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-320640"},{"key":"bibr11-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11489-x"},{"key":"bibr12-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-024-1100-8"},{"key":"bibr13-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1038\/362059a0"},{"key":"bibr14-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/120.10.1723"},{"key":"bibr15-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2013.221"},{"key":"bibr16-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-018-1915-y"},{"key":"bibr17-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1126\/science.8209258"},{"key":"bibr18-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1016\/0896-6273(95)90259-7"},{"key":"bibr19-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1172\/JCI99081"},{"key":"bibr20-17562864251313915","doi-asserted-by":"publisher","DOI":"10.3109\/21678421.2014.964258"},{"key":"bibr21-17562864251313915","doi-asserted-by":"publisher","DOI":"10.3109\/21678421.2015.1049183"},{"key":"bibr22-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000203120.85850.54"},{"key":"bibr23-17562864251313915","first-page":"12","volume":"87","author":"Steinacker P","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"bibr24-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2003715"},{"key":"bibr25-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204705"},{"key":"bibr26-17562864251313915","volume-title":"ENCALS Meeting","author":"Miller TM"},{"key":"bibr27-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102495"},{"key":"bibr28-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27818"},{"key":"bibr29-17562864251313915","first-page":"1","volume":"68","author":"Meyer T","year":"2024","journal-title":"Muscle Nerve"},{"key":"bibr30-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16140"},{"key":"bibr31-17562864251313915","unstructured":"Biogen and Ionis announce Topline phase 1 study results of investigational drug in C9ORF72 Amayotrophic Lateral Sclerosis. News Release, 28 March, 2022, www.biospace.com\/article\/releases\/biogen-and-ionis-announce-topline-phase-1-study-results-of-investigational-drug-in-c9orf72-amyotrophic-lateral-sclerosis\/ (2022, accessed 25 August 2024)."},{"key":"bibr32-17562864251313915","unstructured":"Wave Life Sciences announces topline results from phase 1b\/2a FOCUS-C9 study of WVE-004 for C9orf72-associated amyotrophic lateral sclerosis and frontotemporal dementia. News Release, May 23, 2023, www.globenewswire.com\/news-release\/2023\/05\/23\/2674200\/0\/en\/Wave-Life-Sciences-Announces-Topline-Results-from-Phase-1b-2a-FOCUS-C9-Study-of-WVE-004-for-C9orf72-associated-Amyotrophic-Lateral-Sclerosis-and-Frontotemporal-Dementia.html (2023, accessed 25 August 2024)."},{"key":"bibr33-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01615-z"},{"key":"bibr34-17562864251313915","unstructured":"Biogen and Ionis Announce Topline Phase 1\/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis. News Release, May 16, 2024, https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-and-ionis-announce-topline-phase-12-study-results (2024, accessed 25 August 2024)."},{"key":"bibr35-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-023-00845-8"},{"key":"bibr36-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26045"},{"key":"bibr37-17562864251313915","first-page":"57","volume":"46","author":"Marin B","year":"2017","journal-title":"Int J Epidemiol"},{"key":"bibr38-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15584"},{"key":"bibr39-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104521"},{"key":"bibr40-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2019.1646769"},{"key":"bibr41-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-024-00961-z"},{"key":"bibr42-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23937"},{"key":"bibr43-17562864251313915","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12130-1"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251313915","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864251313915","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251313915","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:36:08Z","timestamp":1741048568000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864251313915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":43,"alternative-id":["10.1177\/17562864251313915"],"URL":"https:\/\/doi.org\/10.1177\/17562864251313915","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"17562864251313915"}}